Back to Journals » Cancer Management and Research » Volume 12

Review

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments

       
Total article views   HTML views PDF downloads Totals
8,760 Dovepress* 7,048+ 958 8,006
PubMed Central* 1,712 373 2,085
Totals 8,760 1,331 10,091
*Since 8 December 2020
Total mentioned Facebook Delicious Reddit Twitter Others
22 0 0 0 8 14

View citations on PubMed Central and Google Scholar